| Patient | Jane Austen |
|---|---|
| Date of birth | 1985-12-16 |
| Identifiers | MRN HR-EN014-SYN; SSN (made up) 000-14-6317 |
| Document date | 2026-04-02 |
| Author | Harriet Pemberton-Okafor, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review after starting replacement: electrolytes, cause, and autoimmune screening. [S]
Ms. Austen returns two weeks after starting hydrocortisone and fludrocortisone. She has missed no doses. Within three days the morning nausea stopped and her appetite returned, and she now eats three meals a day. The lightheadedness on standing has almost gone, and the salt craving is less. She is still tired by late afternoon but has started writing again for an hour each morning. Her back ache is milder. She has practised with the trainer kit and can recite the sick-day rules. She has not yet ordered the medical ID. [S]
| Element | Detail |
|---|---|
| Replacement | Hydrocortisone 10 mg on waking and 5 mg at 2 pm; fludrocortisone 0.1 mg; no missed doses |
| Symptoms | Nausea gone; appetite back; afternoon tiredness; milder back ache |
| Weight | 53.4 kg, up 1.6 kg |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired by late afternoon; appetite good; no fevers or night sweats |
| Cardiovascular | Negative | No lightheadedness, palpitations, or ankle swelling |
| Gastrointestinal | Negative | No nausea, vomiting, or abdominal pain |
| Musculoskeletal | Positive | Mild low back ache by evening |
| Genitourinary | Negative | Periods regular |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Hydrocortisone 10 mg oral tablet, one tablet by mouth on waking | One tablet by mouth on waking | Oral route | 2026-03-19 | active | S |
| Hydrocortisone 5 mg oral tablet, one tablet by mouth at 2 pm | One tablet by mouth at 2 pm | Oral route | 2026-03-19 | active | S |
| Fludrocortisone 0.1 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning | Oral route | 2026-03-19 | active | S |
| Hydrocortisone 100 mg injection kit (with diluent), 100 mg into the thigh muscle once for vomiting, collapse or signs of adrenal crisis, then call 911 | Once, as needed for adrenal crisis; carry at all times | Intramuscular route | 2026-03-19 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-02 | Body height | 170 | cm | S |
| 2026-04-02 | Body weight | 53.4 | kg | S |
| 2026-04-02 | Body mass index (BMI) [Ratio] | 18.5 | kg/m2 | S |
| 2026-04-02 | Systolic blood pressure | 108 | mm[Hg] | S |
| 2026-04-02 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-04-02 | Heart rate | 80 | /min | S |
| 2026-04-02 | Respiratory rate | 14 | /min | S |
| 2026-04-02 | Body temperature | 36.8 | Cel | S |
| 2026-04-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-02 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-02 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-02 | Creatinine [Mass/volume] in Serum or Plasma | 0.86 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 2026-04-02 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 88 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-04-02 | Glucose [Mass/volume] in Serum or Plasma | 88 | mg/dL | 70-139 mg/dL | Normal | S |
| 2026-04-02 | Hemoglobin [Mass/volume] in Blood | 11.9 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-04-02 | Eosinophils [#/volume] in Blood | 0.38 | 10*3/uL | 0-0.5 10*3/uL | Normal | S |
| 2026-04-02 | 21-Hydroxylase Ab [Units/volume] in Serum | 24 | U/mL | Below 1 U/mL: negative | High | S |
| 2026-04-02 | Hemoglobin A1c/Hemoglobin.total in Blood | 5 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes | Normal | S |
| 2026-04-02 | Tissue transglutaminase IgA Ab [Units/volume] in Serum | 0.8 | U/mL | Below 4 U/mL: negative | Normal | S |
| 2026-04-02 | IgA [Mass/volume] in Serum or Plasma | 188 | mg/dL | 70-400 mg/dL | Normal | S |
Vital signs recorded on 2026-04-02; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Brighter; weight 53.4 kg; blood pressure 108/68 seated |
| Skin and mouth | Pigmentation of the face, hands and gums unchanged so far |
| Lymph nodes | No palpable nodes |
| Abdomen | No enlarged liver or spleen |
| Extremities | No ankle edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| About three months of increasing tiredness, loss of 5 kg, darkening of the skin, nausea with bouts of vomiting, low back ache, salt craving and lightheadedness on standing, with low sodium, high potassium and raised eosinophils; adrenal insufficiency suspected and urgent endocrinology testing booked | resolved | confirmed | R53.83 | S — Synthetic presenting concern at the index visit, superseded by the diagnosis at the consultation; its timing echoes the documented break in her health (D). |
| Primary adrenal insufficiency (Addison's disease): no cortisol response to cosyntropin with a markedly raised ACTH, and mineralocorticoid deficiency with raised renin and low aldosterone; on hydrocortisone and fludrocortisone; synthetic modern diagnosis chosen for a historical illness whose cause is disputed | active | confirmed | E27.1 | S — Synthetic modern diagnosis; the historical cause of her illness remains undetermined (R, disputed). |
| Mild normocytic anemia (hemoglobin 11.4 g/dL) with normal ferritin, vitamin B12 and folate | active | confirmed | D64.9 | S — Synthetic finding at intake; it recovers on replacement. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Glucocorticoid dose: weight, energy, appetite, skin pigmentation, and signs of under- or over-replacement | Every visit | Completed today | Weight 53.4 kg, up 1.6 kg; appetite back; no signs of over-replacement; eosinophils 0.38 x10^3/uL, normal |
| Examination | Blood pressure lying and standing | Every visit | Deferred | Missed: blood pressure was taken seated only (108/68). No harm judging by her symptoms and electrolytes today and by the six-week visit, when there was no postural drop. Corrective action: lying and standing blood pressure added to her visit template |
| Laboratory | Mineralocorticoid: salt craving, edema, sodium and potassium | Before treatment, after any fludrocortisone change, then at least yearly | Completed today | Sodium 137, potassium 4.6 mmol/L; creatinine 0.86 mg/dL, eGFR 88; glucose 88 mg/dL |
| Laboratory | Plasma renin activity (with aldosterone at diagnosis) | At diagnosis; after any fludrocortisone change; then at least yearly, aiming for the upper normal range | Due | Six weeks after starting fludrocortisone |
| Self-management | Sick-day rules, emergency injection kit, steroid card, and medical ID | Every visit | Completed today | Rules stated back; practice injection on the trainer; kit and card with her; medical ID ordered today |
| Laboratory | Cause: 21-hydroxylase antibodies; adrenal CT and tuberculosis testing if negative | Once, at diagnosis | Completed today | Positive (24 U/mL): autoimmune adrenalitis; no adrenal imaging or tuberculosis testing needed |
| Examination | Differential for lymphoma: weight, fevers and night sweats, lymph nodes and spleen, LDH, chest X-ray | At diagnosis, then each visit until symptoms and weight have recovered on replacement | Completed today | Weight rising; no fevers or night sweats; no nodes or enlarged spleen |
| Laboratory | Associated autoimmune disease: TSH, vitamin B12, A1c, celiac serology, and menstrual history | At diagnosis, then TSH and the others yearly or with symptoms; FSH if periods change | Completed today | A1c 5.0%; tissue transglutaminase IgA 0.8 U/mL with total IgA 188 mg/dL; TSH and vitamin B12 normal at the first visit; periods regular: no associated disease found |
| Laboratory | Blood count for the normocytic anemia (with ferritin, vitamin B12 and folate at work-up) | Work-up at diagnosis; repeat after the underlying cause is treated (CMID); stop once normal | Completed today | Hemoglobin 11.9 g/dL, rising |
Goal progress:
Guideline basis: Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline (2016); CMID: Clinical Monitoring Intelligence Database, anemia monograph (2026); American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease (2023)
Follow-up: Six-week visit with electrolytes, creatinine, renin, blood count, and lying and standing blood pressure. Follow the sick-day rules for any fever. Next scheduled visit 2026-04-30: six-week review: electrolytes, renin, blood count, and recovery. [S]